ATH-1105
Amyotrophic Lateral Sclerosis (ALS)
Phase 1 (inferred)Under development
Key Facts
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 1 (inferred)
Status
Under development
Company
About LeonaBio
LeonaBio is dedicated to developing novel therapeutics for devastating diseases with limited treatment options, focusing on oncology and neurology. The company's strategy leverages two distinct, late-stage small molecule candidates: lasofoxifene for treatment-resistant metastatic breast cancer and ATH-1105 for ALS. Following a significant financing and licensing deal for lasofoxifene in late 2025, LeonaBio is advancing its Phase 3 ELAINE-3 trial while building a pipeline of earlier-stage compounds. The company is led by an experienced management team with deep expertise in biotech development and finance.
View full company profileOther Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Utreloxastat (PTC857) | PTC Therapeutics | Phase 2 |
| SAR443820/DNL788 | Denali Therapeutics | Phase 2 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 |
| RELYVRIO/ALBRIOZA (AMX0035) | Amylyx Pharmaceuticals | Approved/Commercial |
| AMX0035 | Amylyx Pharmaceuticals | Phase 3 |
| AMX0114 | Amylyx Pharmaceuticals | Phase 1 |
| Taldefgrobep alfa | Biohaven | Phase 2/3 |
| AMT-162 | uniQure | Preclinical |
| AAV-UPF1 | MeiraGTx | Preclinical |
| Tegoprubart | Eledon Pharmaceuticals | Phase 2 |
| Intranasal Foralumab | Tiziana Life Sciences | Phase 2 |
| TDP-43 Program | Korro Bio | Discovery |